Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: Outcome depends on IgG dose

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Sholukh, Anton M ^a,b,c   Byrareddy, Siddappa N ^b,c,e   Shanmuganathan, Vivekanandan ^b   Hemashettar, Girish ^b   Lakhashe, Samir K ^a,b,c   Rasmussen, Robert A ^b,c   Watkins, Jennifer D ^b,c   Vyas, Hemant K ^a,b,c   Thorat, Swati ^b,c   Brandstoetter, Tania ^b   Mukhtar, Muhammad M ^a,b,c   Yoon, John K ^b   Novembre, Francis J ^d   Villinger, Francois ^d,e   Landucci, Gary ^f   Forthal, Donald N ^f   Ratcliffe, Sarah ^g   Tuero, Iskra ^h   Robert Guroff, Marjorie ^h   Polonis, Victoria R ⁱ   Bilska, Miroslawa ^j   Montefiori, David C ^j   Johnson, Welkin E ^k   Ertl, Hildegund C ^l   Ruprecht, Ruth M ^a,b,c   more..

^a SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^j DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k BOSTON COLLEGE   (United States)

^l WISTAR INSTITUTE   (United States)

more..

Author keywords

Enhancement of infection; Heterologous R5 SHIV clade C challenge; Macaque model; Non human primate model; Passive immunization; SHIVIG

Indexed keywords

GAG PROTEIN; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; POLYCLONAL IMMUNOGLOBULIN G ANTIBODY; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MACACA; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS GENOME; VIRUS NEUTRALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; PRIMATES; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIBODIES, NEUTRALIZING; CROSS PROTECTION; DISEASE MODELS, ANIMAL; HIV ANTIBODIES; HIV-1; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 84892466891     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-11-8     Document Type: Article

References (47)

1. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
2. Lakhashe SK, Silvestri G, Ruprecht RM. No acquisition: a new ambition for HIV vaccine development?. Curr Opin Virol 2011, 1:246-253.
3. Prince AM, Horowitz B, Baker L, Shulman RW, Ralph H, Valinsky J, Cundell A, Brotman B, Boehle W, Rey F, et al. Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV. Proc Natl Acad Sci USA 1988, 85:6944-6948.
4. Prince AM, Reesink H, Pascual D, Horowitz B, Hewlett I, Murthy KK, Cobb KE, Eichberg JW. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses 1991, 7:971-973.
5. Eichberg JW, Murthy KK, Ward RH, Prince AM. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG. AIDS Res Hum Retroviruses 1992, 8:1515.
6. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, Hirsch V, Martin MA. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001, 98:658-663.
7. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
8. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
9. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, MartinMalcolm A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5:204-210.
10. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 2010, 16:1117-1119.
11. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, Grisson RD, Wood C, Zhang H, et al. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 2009, 83:1422-1432.
12. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, Chenine AL, Kramer VG, Siddappa NB, Xu W, Else JG, et al. SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 2008, 5:94.
13. Ayash-Rashkovsky M, Chenine AL, Steele LN, Lee SJ, Song R, Ong H, Rasmussen RA, Hofmann-Lehmann R, Else JG, Augostini P, et al. Coinfection with Schistosoma mansoni reactivates viremia in rhesus macaques with chronic simian-human immunodeficiency virus clade C infection. Infect Immun 2007, 75:1751-1756.
14. Rasmussen RA, Ong H, Song R, Chenine AL, Ayash-Rashkovsky M, Hu SL, Polacino P, Else JG, Novembre FJ, Ruprecht RM. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS 2007, 21:1841-1848.
15. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 2006, 80:8729-8738.
16. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668.
17. Brown BK, Wieczorek L, Kijak G, Lombardi K, Currier J, Wesberry M, Kappes JC, Ngauy V, Marovich M, Michael N, et al. The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS ONE 2012, 7:e29454.
18. Carrington M, Alter G. Innate Immune Control of HIV. Cold Spring Harb Perspect Med 2012, 2:a007070.
19. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Martin MA. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002, 76:2123-2130.
20. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, Buckler C, Plishka RJ, Buckler-White A, Martin MA. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 2003, 100:15131-15136.
21. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012, 120:2836-2842.
22. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, Sumpter B, Nguyen H, McClure H, Montefiori D, Cohen JI, Feinberg MB. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004, 101:13026-13031.
23. Hosie MJ, Osborne R, Reid G, Neil JC, Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol 1992, 35:191-197.
24. Siebelink KH, Tijhaar E, Huisman RC, Huisman W, de Ronde A, Darby IH, Francis MJ, Rimmelzwaan GF, Osterhaus AD. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995, 69:3704-3711.
25. Richardson J, Moraillon A, Baud S, Cuisinier AM, Sonigo P, Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997, 71:9640-9649.
26. Hammond SA, Raabe ML, Issel CJ, Montelaro RC. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 1999, 262:416-430.
27. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239:476-481.
28. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010, 328:745-748.
29. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, Shellam GR, McMinn PC. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 2003, 84:1723-1728.
30. Ponnuraj EM, Springer J, Hayward AR, Wilson H, Simoes EA. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis 2003, 187:1257-1263.
31. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 2003, 77:7539-7544.
32. Iankov ID, Pandey M, Harvey M, Griesmann GE, Federspiel MJ, Russell SJ. Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 2006, 80:8530-8540.
33. Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, Musoke P, Mmiro F, Zwerski S, Wigzell H, Falksveden L, et al. Safety and efficacy of HIV hyper immune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011, 58:399-407.
34. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, et al. Limited or no protection by weakly or non-neutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 2011, 108:11181-11186.
35. Takeda A, Ennis FA. FcR-mediated enhancement of HIV-1 infection by antibody. AIDS Res Hum Retroviruses 1990, 6:999-1004.
36. Robinson WE, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988, 1:790-794.
37. Willey S, Aasa-Chapman MM, O'Farrell S, Pellegrino P, Williams I, Weiss RA, Neil SJ. Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection. Retrovirology 2011, 8:16.
38. Stoiber H, Soederholm A, Wilflingseder D, Gusenbauer S, Hildgartner A, Dierich MP. Complement and antibodies: a dangerous liaison in HIV infection?. Vaccine 2008, 26(Suppl 8):I79-I85.
39. NIH discontinues immunizations in HIV vaccine study. http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx.
40. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67:3978-3988.
41. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005, 12(12):11.
42. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ, et al. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE 2011, 6:e18207.
43. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
44. Gomez-Roman VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods 2006, 308:53-67.
45. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010, 408:1-13.
46. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin NL, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009, 206:1117-1134.
47. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289.